Last updated: February 25, 2026
Allegra-D 24 Hour combines fexofenadine (antihistamine) and pseudoephedrine (decongestant). Its formulation relies on specific excipients to ensure bioavailability, stability, and patient safety. Optimizing excipient selection can improve manufacturing efficiency, patent durability, and market fragmentation.
What Are the Key Excipients in Allegra-D 24 Hour?
Allegra-D 24 Hour contains several excipients that support its efficacy and stability:
- Fexofenadine hydrochloride (active)
- Pseudoephedrine hydrochloride (active)
- Microcrystalline cellulose (filler/disintegrant)
- Hydroxypropyl cellulose (binder)
- Lactose monohydrate (filler)
- Magnesium stearate (lubricant)
- Polyethylene glycol (PEG) (stabilizer)
- Sodium starch glycolate (disintegrant)
- Titanium dioxide (film coating)
- Red and yellow iron oxides (colorants)
Excipient Strategy Implications
Bioavailability and Stability
- Disintegrants (e.g., sodium starch glycolate) facilitate drug release.
- Lactose and microcrystalline cellulose support tablet integrity and aid dissolution.
- PEG stabilizes the drug and enhances solubility.
Manufacturing Efficiency
- Use of common excipients like magnesium stearate simplifies scale-up.
- Compatibility of excipients with active ingredients reduces batch failures.
- Potential for controlled-release formulations hinges on excipient choice, extending patent life and market share.
Patient Safety & Compliance
- Colorants and fillers are selected for minimal allergenic potential.
- Taste-masking agents may be incorporated, although not characteristic of Allegra-D 24 Hour in its current form.
Intellectual Property and Patent Opportunities
Existing Patent Landscape
- Compound patents: Fexofenadine and pseudoephedrine are expired or near expiry, shifting focus to formulation patents.
- Formulation patents: Cover excipient combinations, coating processes, and controlled-release mechanisms. For instance, patents filing around 2000s protect the tablets' specific excipient matrix.
Opportunities for Innovation
- Novel excipient blends that improve bioavailability or reduce excipient load.
- Controlled or sustained release formulations, utilizing polymers like ethyl cellulose or hydroxypropyl methylcellulose (HPMC).
- Taste-masked formulations for pediatric and senior markets.
- Patent around excipient manufacturing processes to improve stability or reduce costs.
Commercial Opportunities
Market Trends
- The global antihistamine market is forecasted to reach USD 2.4 billion by 2027 (Fortune Business Insights, 2022).
- Pseudoephedrine is subject to regulatory restrictions; formulations that minimize its use are in demand.
Opportunities in Formulation Variations
- Reduced excipient content enhances purity and reduces regulatory scrutiny.
- Extended-release formats can command premium pricing.
- Combination products with other active agents for multi-symptom relief.
Regulatory and Market Dynamics
- FDA and EMA policies favor formulations with well-established excipients.
- Patent challenges on existing formulations signal an opportunity for new, patentable formulations.
Competitor Strategy
- Focus on novel excipient matrices to get around patent expirations.
- Develop differentiated formulations catering to children or elderly patients, requiring unique excipient choices.
Key Takeaways
- Excipient choices in Allegra-D 24 Hour influence bioavailability, stability, and manufacturability.
- Patent opportunities exist in novel excipient combinations and controlled-release formulations.
- Market growth in allergy medications favors innovative, patentable formulations with improved patient compliance.
- Regulatory considerations favor excipients with proven safety profiles.
- Formulation innovation can extend product life cycle and enhance market share.
FAQs
1. What are the main challenges inFormulating Allegra-D 24 Hour?
Ensuring stability of pseudoephredrine, optimizing bioavailability, and maintaining low allergenic potential of excipients.
2. How can excipient innovation extend the patent life of Allegra-D 24 Hour?
By developing new excipient matrices or controlled-release systems not previously patented.
3. Are there regulatory concerns with excipients used in Allegra-D 24 Hour?
Excipients like lactose, microcrystalline cellulose, and magnesium stearate are well-established, minimizing regulatory hurdles.
4. What alternative excipients could replace current ones for improved performance?
Polymers like HPMC or ethyl cellulose for controlled release; sweeteners or flavoring agents for taste masking.
5. How does market demand influence excipient selection?
Consumer preference for ease of swallowing, taste, and safety guides excipient choices, especially in pediatric and geriatric formulations.
References
[1] Fortune Business Insights. (2022). Global Antihistamines Market Size, Share & Industry Analysis.
[2] U.S. FDA. (2020). Inactive Ingredient Database.
[3] European Medicines Agency. (2021). Guideline on Excipients.
